6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Titel:
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Auteur:
Earl, Helena M Hiller, Louise Vallier, Anne-Laure Loi, Shrushma McAdam, Karen Hughes-Davies, Luke Harnett, Adrian N Ah-See, Mei-Lin Simcock, Richard Rea, Daniel Raj, Sanjay Woodings, Pamela Harries, Mark Howe, Donna Raynes, Kerry Higgins, Helen B Wilcox, Maggie Plummer, Chris Mansi, Janine Gounaris, Ioannis Mahler–Araujo, Betania Provenzano, Elena Chhabra, Anita Abraham, Jean E Caldas, Carlos Hall, Peter S McCabe, Christopher Hulme, Claire Miles, David Wardley, Andrew M Cameron, David A Dunn, Janet A
Verschenen in:
Lancet
Paginering:
Jaargang 393 () nr. 10191 pagina's 2599-2612
Jaar:
2019
Inhoud:
Uitgever:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license